• AZD6482: Designing Better PI3Kβ Assays

  2026-09-18

  AZD6482 is a highly selective PI3Kβ inhibitor with applications spanning kinase, platelet, and metabolic research. This guide explains how to use its selectivity while avoiding misinterpretation when designing assays inspired by RNA-foci studies in myotonic dystrophy.

• Phillygenin Signaling in Diabetic Nephropathy

  2026-09-18

  The reference study shows that phillygenin reduces hyperglycemia-associated inflammation and apoptosis in podocytes and improves renal injury in db/db mice. Its main contribution is the integration of TLR4/MyD88/NF-κB suppression with restoration of PI3K/AKT/GSK3β signaling, while its preclinical design leaves questions about direct pathway causality and clinical translation.

• DDRGK1 UFMylation and STAT3 in Osteoarthritis

  2026-09-17

  The reference study identifies DDRGK1-dependent UFMylation as a regulatory brake on STAT3 phosphorylation and nuclear translocation during osteoarthritis progression. By integrating human cartilage analysis, cartilage-specific mouse genetics, multi-omics, biochemical interaction assays, and pharmacological rescue, it provides a mechanistic framework for linking loss of DDRGK1 to inflammatory cartilage degeneration.

• Tamoxifen Workflows for CreER-Mediated Knockout

  2026-09-17

  Tamoxifen is a versatile selective estrogen receptor modulator for inducible genetics, cancer biology, and pathway validation. This workflow-focused guide shows how to use it in CreER-mediated gene knockout studies while controlling solubility, recombination variability, estrogen-sensitive confounding, and assay interpretation.

• Angiotensin I/II (1-5) Workflow Guide

  2026-09-16

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving blood pressure and aldosterone-related assays. It should be used only in validated cardiovascular or renal workflows, with solvent-matched controls and cautious interpretation because directly matched paper evidence was not available for this product-specific application.

• Agatoxin-IVA and Nicotinic Activation of Vagal Neurons

  2026-09-16

  The reference study showed that agatoxin-IVA-sensitive voltage-dependent calcium channels connect nicotinic receptor activation to both presynaptic glutamate release and postsynaptic excitation in cardiac vagal neurons. Its selective pharmacological design separated Cav2.1/P-type channel involvement from L-, N-, and Q-type channel contributions, providing a useful framework for synaptic transmission research.

• AO/PI Staining Solution for Mechanistic Assays

  2026-09-15

  AO/PI Staining Solution provides fluorescence-based cell counting that separates membrane-intact from membrane-compromised cells. This guide explains how to use dual fluorescent DNA dyes as a quality-control and decision tool in diabetic nephropathy research, rather than treating viability as a standalone endpoint.

• Tamoxifen Workflows for CreER and Disease Models

  2026-09-15

  Learn how Tamoxifen supports temporal gene control, breast cancer research, and mechanistic disease modeling. This workflow-focused guide pairs formulation and induction strategies with insights from a study of recurrent airway inflammation and GZMK-expressing CD8+ T cells.

• ALC-0315 for Reproducible LNP Assays

  2026-09-14

  Learn how ALC-0315 (SKU B8595) can support controlled lipid nanoparticle workflows for cell viability, proliferation, and cytotoxicity studies. This scenario-based guide connects material quality, solvent compatibility, mixing, and batch interpretation with evidence from recent LNP research.

• WAY-100635 for Reliable 5-HT1A Assays

  2026-09-14

  Learn how WAY-100635 (SKU A3933) can strengthen receptor-mechanism controls in cell viability, proliferation, cytotoxicity, and pain-related studies. This scenario-based guide covers formulation, protocol design, interpretation, vendor evaluation, and the limits of translating behavioral findings into cellular assays.

• Fluoxetine HCl: Mechanism and Research Workflows

  2026-09-13

  Fluoxetine HCl is a selective serotonin reuptake inhibitor used to study serotonin transporter activity, 5HT2C signaling, neurogenesis, and reward-related behavior. Its molecular effects are well established, while developmental-exposure findings in mice define a research model rather than a clinical treatment conclusion.

• SB203580: p38 MAPK Assay Workflows

  2026-09-12

  Use SB203580 to separate p38-dependent stress signaling from the MAPK/ERK responses implicated in vascular lipid toxicity. This practical guide covers stock preparation, branch-specific controls, nanoparticle-exposure assays, dose selection, and troubleshooting for reproducible cell-based experiments.

• Everolimus (RAD001) Cancer Assay Workflows

  2026-09-11

  Everolimus (RAD001) turns mTOR pathway biology into measurable changes in cancer-cell growth, survival, and signaling. This workflow emphasizes exposure-aware dosing, time-resolved viability, and orthogonal apoptosis measurements so researchers can distinguish cytostatic effects from true cell killing.

• Mouse Neutrophil Cell Isolation Kit: Assay Design

  2026-09-11

  Discover how the Mouse Neutrophil Cell Isolation Kit supports activation-conscious assay design across bone marrow, blood, and spleen workflows. This guide connects negative selection with practical interpretation of neutrophil-targeted mRNA nanovaccine studies.

• Rotavirus Infection Reprograms Nrf2 Redox Defense

  2026-09-10

  The reference study shows that rotavirus infection produces a biphasic Nrf2 response: an early, redox-sensitive increase is followed by marked Nrf2 depletion and loss of antioxidant transcription. Its mechanistic analysis implicates proteasome-associated, K48-linked ubiquitination rather than canonical Keap1/Cul3-Rbx1 turnover alone, providing a useful framework for studying viral disruption of cellular stress adaptation.

8004 records 1/534 page Next 12345 下5页 Last page